The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics
Open accessAbstract
Osteosarcoma, the most common malignant tumor of the bone, seriously influences people’s lives and increases their economic burden. Conventional chemotherapy drugs achieve limited therapeutic effects owing to poor targeting and severe systemic toxicity. Nanocarrier-based drug delivery systems can significantly enhance the utilization efficiency of chemotherapeutic drugs through targeting ligand modifications and reduce the occurrence of systemic adverse effects. A variety of ligand-modified nano-drug delivery systems have been developed for different targeting schemes. Here we review the biological characteristics and the main challenges of current drug therapy of OS, and further elaborate on different targeting schemes and ligand selection for nano-drug delivery systems of osteosarcoma, which may provide new horizons for the development of advanced targeted drug delivery systems in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164 · cited 1×
“Active cellular targeting of nano-drug delivery systems is achieved by modifying high-affinity ligands or aptamers to target tumor cells and deliver antitumor drugs [81] (Fig.”
BackgroundSelf-citationNew Horizons in the Treatment of Osteosarcoma
Meltzer, P. S., & Helman, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2103423 · Cited by 672
Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., Comber, H., Dimitrova, N., Leinonen, M. K., Siesling, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30445-x · Cited by 516
Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles
Arvizo, R. R., Miranda, O. R., Moyano, D. F., Walden, C. A., Giri, K., Bhattacharya, R., Robertson, J. D., Rotello, V. M., Reid, J. M., & Mukherjee, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024374 · Cited by 403
Liu, S., Ou, H., Li, Y., Zhang, H., Liu, J., Lu, X., Kwok, R. T. K., Lam, J. W. Y., Ding, D., & Tang, B. Z. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c07193 · Cited by 277
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer
Momcilovic, M., Jones, A., Bailey, S. T., Waldmann, C. M., Li, R., Lee, J. T., Abdelhady, G., Gomez, A., Holloway, T., Schmid, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1715-0 · Cited by 214
Cited by
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,062
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Hydroxyapatite: A journey from biomaterials to advanced functional materials
Mondal, S., Park, S., Choi, J., Vu, T. T. H., Doan, V. H. M., Vo, T. T., Lee, B., & Oh, J. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.103013 · Cited by 344
Lim, Y. N., Ryu, I. S., Jung, Y.-J., Helmlinger, G., Kim, I., Park, H. W., Kang, H., Lee, J., Lee, H. J., Lee, K. S., et al. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102340 · Cited by 17
El-khawaga, A. M., Youssef, O. I., El-dydamoni, O. A., Ragab, W. M., & Mohammed, R. A. E. (2026) · European Journal of Medical Research · doi:10.1186/s40001-025-03804-9 · Cited by 14
Metadata
- Authors
- Shi, P., Cheng, Z., Zhao, K., Chen, Y., Zhang, A., Gan, W., & Zhang, Y.
- Venue
- Journal of Nanobiotechnology
- Published
- 2023-03-22
- Volume
- 21
- Issue
- 1
- Pages
- 103-103
- ISSN
- 1477-3155 (ISSN-L)
- OpenAlex
- W4328050642
- Cited by
- 200
- References
- 11
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. https://app.cochat.ai/papers/10.1186/s12951-023-01826-1
- The paper
- Shi, P., Cheng, Z., Zhao, K., Chen, Y., Zhang, A., Gan, W., & Zhang, Y. (2023). Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-023-01826-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.